CorMedix Faces A Hard Reset As CMS Reimbursement Headwinds Emerge [Seeking Alpha]
CorMedix Inc. (CRMD)
NASDAQ:AMEX Investor Relations:
cormedix.com
Company Research
Source: Seeking Alpha
FY26 revenue guidance of $300-$320 million is a significant drop from FY25's $400 million, reflecting pricing pressure and regulatory headwinds. Despite robust 4Q25 results and strong liquidity ($148 million cash), clinical trial timing and outcomes for Rezzayo and DefenCath TPN add uncertainty. CRMD now trades at a deep valuation discount (2.8x forward earnings), with the market heavily discounting profitability and pipeline potential. PonyWang/E+ via Getty Images Thesis CorMedix ( CRMD ) stock yesterday saw a pretty big sell-off in the range of 33%. That's because the company expects some significant headwinds in the form of DefenCath's Transitional Drug Add-On Payment, which will now transition This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I
Show less
Read more
Impact Snapshot
Event Time:
CRMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRMD alerts
High impacting CorMedix Inc. news events
Weekly update
A roundup of the hottest topics
CRMD
News
- CorMedix: The Post-TDAPA Hangover Arrived Early (Rating Downgrade) [Seeking Alpha]Seeking Alpha
- CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- CorMedix (NASDAQ:CRMD) had its price target lowered by analysts at Needham & Company LLC from $16.00 to $15.00. They now have a "buy" rating on the stock.MarketBeat
- How Recent Q3 Updates Are Shaping The CorMedix (CRMD) Investment Story [Yahoo! Finance]Yahoo! Finance
- A Look At CorMedix (CRMD) Valuation After 2026 Guidance Shift And Executive Changes [Yahoo! Finance]Yahoo! Finance
CRMD
Earnings
- 11/12/25 - Beat
CRMD
Sec Filings
- 1/8/26 - Form 8-K
- 1/6/26 - Form 4
- 1/6/26 - Form 4
- CRMD's page on the SEC website